JPT Peptide Technologies GmbH products

Cell Therapy & Vaccine Development

Neo-Epitope Prioritization

Neo-epitopes are important targets for individualized cancer immunotherapy. Recent advancements in next generation sequencing and bioinformatic approaches to predict immunogenicity of neo-epitopes improved target selection for therapy. However, in many cases only a fraction of predicted epitopes generate a specific T-cell response. Therefore, various assay techniques such as ELISpot, MHC-binding, or mass -spectrometry are being applied to confirm and prioritize neo-epitopes for individualized therapies. The ability to create meaningful and truly patient-individualized sets of neo-epitopes ultimately requires high-throughput formats and thus large numbers of small scale, high quality, and low cost peptides, in very short times.

PepMix - Clinical Peptides

Clinical peptides and PepMix Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics, cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, high quality peptide partner. JPT is that partner with its outstanding know-how on peptide antigen formats, peptide specifications and formulation, peptide manufacturability manufacturability and properties as well as critical analytical release testing and batch documentation warranting smooth transition from research to clinical application.

PepSup - Cell Activation Kit

PepSup is a highly standardized, peptide-based cell activation (cell stimulation) assay designed to produce short-term culture supernatants for analysis of cytokines or other mediators of interest. We create your PepSup Cell Activation Kit with your choice of PepMix Peptide Pools Antigen Peptides or custom peptides using a specialized culture medium. A PepSup kit contains sufficient reagents for 6 cell stimulations with the pertinent positive and negative controls.